Hinge Health (NYSE:HNGE) Given New $145.00 Price Target at Truist Financial

Hinge Health (NYSE:HNGE) had its price objective upped by equities research analysts at Truist Financial from $112.00 to $145.00 in a note issued to investors on Tuesday, Benzinga reports. The brokerage presently has a “buy” rating on the stock. Truist Financial‘s target price points to a potential upside of 23.41% from the stock’s previous close.

HNGE has been the subject of several other reports. Barclays increased their price objective on Hinge Health from $100.00 to $110.00 and gave the stock an “overweight” rating in a research note on Monday, October 12th. Evercore restated an “outperform” rating and issued a $105.00 target price on shares of Hinge Health in a research note on Wednesday, August 5th. KeyCorp upped their target price on shares of Hinge Health from $125.00 to $140.00 and gave the stock an “overweight” rating in a report on Friday, October 16th. Citizens Jmp increased their target price on shares of Hinge Health from $96.00 to $107.00 and gave the stock a “market outperform” rating in a research report on Wednesday, August 5th. Finally, Bank of America began coverage on shares of Hinge Health in a research report on Tuesday, September 29th. They issued a “buy” rating and a $110.00 price target on the stock. One analyst has rated the stock with a Strong Buy rating, fifteen have issued a Buy rating and three have given a Hold rating to the stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average target price of $117.40.

Hinge Health Stock Up 1.7%

HNGE traded up $2.01 during midday trading on Tuesday, reaching $117.49. 1,397,655 shares of the company’s stock were exchanged, compared to its average volume of 1,623,602. The business has a 50-day simple moving average of $98.66 and a two-hundred day simple moving average of $67.35. The firm has a market capitalization of $9.48 billion, a price-to-earnings ratio of 91.85 and a beta of 1.37. Hinge Health has a one year low of $30.08 and a one year high of $118.86.

Hinge Health (NYSE:HNGE) last released its quarterly earnings data on Monday, November 2nd. The company reported $0.71 earnings per share for the quarter, beating the consensus estimate of $0.27 by $0.44. The company had revenue of $234.97 million for the quarter. Hinge Health had a return on equity of 51.60% and a net margin of 15.15%. The company’s revenue for the quarter was up 52.4% on a year-over-year basis. During the same quarter in the prior year, the company posted ($0.02) earnings per share. As a group, research analysts anticipate that Hinge Health will post 1.25 EPS for the current fiscal year.

Insiders Place Their Bets

In other news, CFO James Budge sold 55,561 shares of the company’s stock in a transaction that occurred on Thursday, September 10th. The shares were sold at an average price of $89.45, for a total transaction of $4,969,931.45. Following the transaction, the chief financial officer directly owned 349,062 shares in the company, valued at approximately $31,223,595.90. This represents a 13.73% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Daniel Perez sold 150,000 shares of the company’s stock in a transaction that occurred on Thursday, September 10th. The stock was sold at an average price of $89.44, for a total transaction of $13,416,000.00. Following the transaction, the chief executive officer owned 35,470 shares in the company, valued at $3,172,436.80. The trade was a 80.88% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold a total of 1,024,581 shares of company stock worth $95,632,761 in the last three months. Company insiders own 18.92% of the company’s stock.

Institutional Inflows and Outflows

Several institutional investors have recently bought and sold shares of HNGE. 11.2 Capital Management LLC acquired a new stake in shares of Hinge Health in the 2nd quarter valued at $204,566,531. Assenagon Asset Management S.A. boosted its holdings in Hinge Health by 2,141.9% in the third quarter. Assenagon Asset Management S.A. now owns 1,854,922 shares of the company’s stock valued at $180,373,000 after acquiring an additional 1,772,182 shares during the last quarter. Wellington Management Group LLP increased its position in Hinge Health by 169.7% in the second quarter. Wellington Management Group LLP now owns 1,205,584 shares of the company’s stock worth $100,063,000 after purchasing an additional 758,594 shares during the period. Arrowstreet Capital Limited Partnership raised its holdings in Hinge Health by 225.7% during the 1st quarter. Arrowstreet Capital Limited Partnership now owns 1,163,187 shares of the company’s stock worth $44,852,000 after purchasing an additional 806,007 shares during the last quarter. Finally, Estuary Capital Management LP acquired a new position in Hinge Health during the 1st quarter valued at about $15,201,000.

Key Stories Impacting Hinge Health

Here are the key news stories impacting Hinge Health this week:

• Positive Sentiment: Q3 results exceeded expectations: Hinge Health reported earnings of $0.71 per share versus consensus estimates of $0.27 and revenue of $234.97 million, up 52.4% year over year. The company also posted a 15.15% net margin and 51.6% return on equity. Hinge Health quarterly earnings report
• Positive Sentiment: Revenue outlook was raised above consensus: Hinge Health guided fourth-quarter 2026 revenue to $249 million-$251 million, compared with the $239.2 million consensus estimate. Full-year revenue guidance of $879 million-$881 million also exceeded the $858.5 million consensus. Hinge Health revenue outlook
• Positive Sentiment: Analysts raised price targets: RBC lifted its target to $135 and maintained an “outperform” rating; Canaccord raised its target to $134 with a “buy” rating; and Stifel increased its target to $135, also retaining a “buy” rating. These targets imply roughly 16% upside from recent trading levels.
• Neutral Sentiment: Management highlighted continued expansion of its technology-enabled care platform and is targeting an integrated gastrointestinal program in summer 2027, providing a potential longer-term growth catalyst.
• Negative Sentiment: The earnings beat may have been largely anticipated, and some coverage indicated results missed the higher “whisper” expectations. With HNGE trading near its 52-week high and at a high valuation, investors may be taking profits despite the favorable fundamental update. Hinge Health earnings expectations analysis

About Hinge Health

Hinge Health is a digital healthcare company focused on musculoskeletal (MSK) conditions, including back and joint pain. The company provides virtual care programs designed to help members manage pain, improve mobility and reduce the need for more costly or invasive treatments.

Its platform combines personalized exercise therapy, behavioral support, education and access to clinical professionals. Hinge Health also uses technologies such as motion-sensing wearable devices and artificial intelligence to help guide exercises, monitor progress and tailor care plans to individual needs.

Hinge Health primarily serves employers and health plans, which offer its programs to eligible members in the United States.